GlassScriptPhysician profile
Vivarian Malcolm
NPI 1558089607
$2,130.06
in general payments reported to CMS, 2019-2025
28 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.55 · 2023: $813 · 2024: $819 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $234.33 | 2023-2025 | Veozah |
| Abbvie INC. | $227.88 | 2023-2025 | |
| Lilly USA, LLC | $220.91 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $207.83 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $122.21 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.89 | 2023-2024 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $109.62 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $109.53 | 2022-2023 | Rexulti |
| Novo Nordisk INC | $104.61 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $86.43 | 2023-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.85 | 2023-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $59.25 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Alk-Abello, INC | $57.57 | 2024 | Grastek, Odactra, Ragwitek |
| Dexcom, INC. | $48.87 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $41.09 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.78 | 2023 | |
| Nestle Healthcare Nutrition INC. | $38.97 | 2023 | |
| Idorsia Pharmaceuticals US INC | $34.74 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $32.04 | 2023 | |
| Lundbeck LLC | $27.86 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $23.92 | 2025 | Gardasil 9, Capvaxive |
| Insmed, INC. | $22.71 | 2025 | Arikayce |
| Philips North America LLC | $21.66 | 2024 | (Ck7) Extended Holter |
| Shield Therapeutics INC | $20.43 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.23 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.03 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $16.76 | 2025 | Zoryve |
| Esperion Therapeutics, INC. | $14.06 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivarian Malcolm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.